U.S., Oct. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07215650) titled 'Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)' on Sept. 24.
Brief Summary: The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Generalized Myasthenia Gravis.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Generalized Myasthenia Gravis
Intervention:
DRUG: Cizutamig
Cizutamig will be dosed according to the protocol
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Candid Therapeutics
Disclaimer: Curated by HT Syndication....